Transcode Therapeutics (RNAZ) Shares Issued (2023 - 2026)

Transcode Therapeutics (RNAZ) has reported Shares Issued for 4 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Issued rose 45.64% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (up 45.64% YoY), and the FY2025 full-year result was $916968.0, up 2394.95% from the prior year.
• Shares Issued was little changed at $1.2 million in Q2 2026 per RNAZ's latest filing, from $1.2 million in the prior quarter.
• Across five years, Shares Issued topped out at $1.2 million in Q1 2026 and bottomed at $679.0 in Q4 2023.
• Historically, Shares Issued has averaged $721453.4 across 4 years, with a median of $833683.0 in 2025.
• The sharpest annual moves came in 2024 and 2026: Shares Issued soared 5312.81% in 2024, then soared 45.64% in 2026.
• Over 4 years, Shares Issued stood at $679.0 in 2023, then jumped by 5312.81% to $36753.0 in 2024, then surged by 2394.95% to $916968.0 in 2025, then surged by 32.42% to $1.2 million in 2026.
• According to Business Quant data, Shares Issued over the past three periods registered $1.2 million, $1.2 million, and $916968.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.